The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.50
Bid: 31.00
Ask: 32.00
Change: 0.25 (0.80%)
Spread: 1.00 (3.226%)
Open: 31.25
High: 31.75
Low: 31.25
Prev. Close: 31.25
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

13 Sep 2023 07:00

RNS Number : 2324M
Duke Royalty Limited
13 September 2023
 

13 September 2023

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, is pleased to provide the following trading and operational update for its first quarter of the financial year 2024, ending 30 June 2023 ("Q1 FY24"). The Company also provides guidance on trading for its second quarter, ending 30 September 2023 ("Q2 FY24").

 

Q1 FY24 Financial Highlights:

 

· Recurring cash revenue for Q1 FY24 reached a new record of £6.0 million, an increase of 17% over Q1 FY23, and a £300,000 increase on the prior quarter

· The £6.0 million for the quarter meant Duke delivered an average monthly recurring cash revenue of £2.0 million for the first time in the Company's history, a significant milestone

· Q1 FY24 total cash revenue reached £7.8 million, marking another quarterly cash revenue record, surpassing the previous record of £6.7 million in Q4 FY22, on account of the Instor buyback

· 0.70p interim dividend paid out in April 2023

Overview of quarterly revenue growth:

 

Recurring Cash Revenue*

Total Cash Revenue**

Q1 FY23

£5.1 million

£5.1 million

Q2 FY23

£5.3 million

£5.3 million

Q3 FY23

£5.6 million

£5.6 million

Q4 FY23

£5.7 million

£5.8 million

Q1 FY24

£6.0 million

£7.8 million

 

* Recurring cash revenue excludes buyback premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's royalty partners plus cash gains received from the sales of equity assets and buyback premiums

 

 

Q1 FY24 Operational Highlights:

· In May 2023, Duke announced the successful exit of its investment in royalty partner Instor Solutions, Inc. Duke received net cash of US$11.2 million at closing, delivering a total gain of US$2.4 million and a triple-digit IRR

· Duke also completed two material follow-on investments in the quarter as follows:

- a £1.9 million investment into New Path Fire and Security to facilitate its acquisition of BDI Security Limited

- a £1.8 million investment int Tristone Healthcare to enable the company to complete its acquisition of South West Intervention Service Limited

 

Financial Forecast for Q2 FY24:

 

· Based on current trading, Duke expects to achieve recurring cash revenue of £6.2 million in Q2 FY24

· The £6.2 million of cash revenue would represent a 17% year-on-year increase (Q2 FY23: £5.3 million) and a further increase on Q1 FY24

 

Neil Johnson, CEO of Duke Royalty, said:

 

"We are pleased to report another quarter marked by record-breaking cash performance, underpinned by solid growth. This underscores the resilience of Duke's business model, especially in the face of ongoing economic challenges. Looking ahead, we remain confident that the consistent quarterly growth we have generated in recurring revenue will continue, and Duke is committed to working with our partners for their long-term growth."

 

Change of Name of Nominated Adviser and Joint Broker

 

The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Cavendish Securities plc following completion of its own corporate merger.

 

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 730 613

Cavendish Securities plc 

(Nominated Adviser

and Joint Broker)

 

Stephen Keys / Callum Davidson / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell / Alice Cho / Matthew Elliott

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLLLFXKLBBBB
Date   Source Headline
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.